CRISPR Therapeutics (CRSP -1.64%) isn't a stock that's wanting for reasons to invest. Between the solid launch of its first commercialized therapy and a promising pipeline that's continuing to deliver, this biotech is on track for growth. Plus, investors just got another big green flag to invest in its stock.Here's what you need to know.This new development augurs a bright futurePer the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the Food and Drug Administr ...

Innovation holds the key in the ever-evolving biotech sector, and most companies in this sector are striving to develop a drug or treatment using a breakthrough technology.Biotech companies with promising gene therapies in their portfolio/pipeline have garnered investors’ attention in 2024. Interest in this space renewed following the FDA approval of a few gene therapies toward the end of 2023.Consequently, some pharma/biotech bigwigs scurried for a lucrative catch in the space, either through licensing dea ...

Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in 2025.The Food and Drug Administration (FDA) approved CRISPR Therapeutics' (CRSP 1.05%) first treatment last December, and its successful launch could push the stock much higher.  Investment bank analysts also expect Iovance Biotherapeutics (IOVA 0.13%) to soar in 2025.Before chasing exciting price targets, thou ...

CRISPR Therapeutics (CRSP -3.57%) is recognized as a pioneer in the field of gene therapy. This biotechnology has the potential to revolutionize medicine through precise modifications of a person's DNA to treat and cure genetic diseases. In 2023, the company's Casgevy product for sickle cell disease became the first-ever CRISPR-based therapy approved by the Food and Drug Administration (FDA) as an important company milestone.Nevertheless, commercialization has been slow, with the market already waiting for ...

Shares of CRISPR Therapeutics AG (CRSP) have gained 0.8% over the past four weeks to close the last trading session at $51.17, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $81 indicates a potential upside of 58.3%.The mean estimate comprises 24 short-term price targets with a standard deviation of $34.31. While the lowest estimate of $30 indicates a 41.4% decline from the cur ...

Ark Invest chief Cathie Wood is known for scooping up shares of innovators early in their growth stories and holding on for the long term. The idea is to get in on these players for a bargain price, and then benefit as they launch products and revenue gains momentum. This takes time, but patient investors could score a major win by following Wood's strategy -- and by picking up a couple of her favorite stocks. Over the past several weeks, Wood has added to one of her key positions, a stock that's lost about ...

On Nov. 21, shares of CRISPR Therapeutics (CRSP 3.44%) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene therapies. After all, it's been less than a year since regulators in the U.S. and E.U. approved its first therapy, Casgevy, to treat two blood-based disorders.Casgevy's initial launch hasn't been as exciting as investors and its partner, Vertex Pharmaceuticals (VRTX 0.13%), had hoped. Less than a year into the launch ...

Godzilla and King Kong surely weren't born big. They began small and grew over time to their gargantuan sizes even if the movies don't tell their childhood stories.Likewise, huge companies of today were once much smaller (unless perhaps they were spin-offs). Investors who spotted them early had opportunities to make fortunes.Can you still find such monsters in the making? Three Motley Fool contributors think so. Here's why they think biotech stocks CRISPR Therapeutics (CRSP 3.44%), Summit Therapeutics (SMMT ...

Summary of CRISPR Therapeutics AG Conference Call Company Overview - CRISPR Therapeutics AG (NASDAQ: CRSP) is celebrating its 10th anniversary, founded on the Nobel Prize-winning discovery of CRISPR/Cas9 for genome editing. The company has developed transformative medicines, including Casgevy for beta thalassemia and sickle cell disease, in partnership with Vertex. [4][5] Key Developments Casgevy Launch - The launch of Casgevy has been slower than anticipated, with only one patient treated out of 40 who had cells collected. Barriers include reimbursement issues and the complexity of scheduling treatments, likened to elective surgeries. [6][8] - Despite the slow start, demand for Casgevy is strong globally, with significant payer support in the US, Middle East, and Europe. [7][8] - The company is optimistic about the revenue potential, estimating that with 75 activated treatment centers (ATCs) performing a minimum of 10 treatments per year, substantial revenue could be generated. [9] - The company plans to invest further in capacity to meet anticipated demand. [9][15] Patient Demographics and Market Insights - The patient demographic is not typical; many patients are motivated by severe pain and fear of early death, leading to a potential increase in treatment uptake as more success stories emerge. [11][12] - There are approximately 25,000 severe patients in the US and an estimated 30,000 in the Middle East, with more patients identified in the UK and France than previously thought. [12] Competitive Landscape - The competitive landscape for sickle cell disease therapies is evolving, with some competitors facing challenges that may benefit CRISPR. The company views the development of more treatment options as positive for patients. [16] - CRISPR aims to achieve profitability by 2028, with a current cash reserve of $2 billion providing a buffer for ongoing investments. [18] In Vivo Programs - CRISPR is advancing two in vivo programs targeting ANGPTL3 and LPA, with ongoing dose escalation studies. LPA is gaining attention as a significant cardiovascular risk factor. [19][20] - The company anticipates pivotal data from Novartis and Amgen regarding LPA, which could inform their strategy moving forward. [21][22] CAR-T Platform - CRISPR is developing next-generation CAR-T therapies, with promising edits (Regnase 1 and TGF beta knockouts) enhancing efficacy and durability. [30][31] - The company is in discussions with regulators regarding the path to registration for oncology applications and is expanding into autoimmune diseases. [33] Differentiation in Autoimmune Space - CRISPR's allogeneic CAR-T approach is positioned as a scalable solution compared to autologous therapies, which are slower to enroll and carry risks. [35][36] - The company is focusing on optimizing conditioning regimens for autoimmune applications, starting with standard flu-side conditioning. [39] RegenMed Platform - CRISPR is observing advancements in IPS cell-based organ development, with regulatory openness to trials potentially accelerating progress in diabetes treatments. [42] Key Catalysts Ahead - Investors should focus on upcoming data releases related to Casgevy, in vivo programs (LPA and ANGPTL3), oncology data, and autoimmune developments over the next 9 to 12 months. [44]

CRISPR Therapeutics’ (CRSP) shares have lost 6.6% in the past two weeks compared with the industry’s 8.4% decline, as seen in the chart below. The stock has underperformed the sector and the S&P 500 index. Shares of the company are also currently trading below its 50-day and 200-day moving averages.CRSP Stock Performance Image Source: Zacks Investment ResearchThe drop in the share price is likely due to the decline of the drug/biotech sector in the past couple of months due to lower-than-expected third-quar ...